TL;DR
- 1.SS-31 (Elamipretide) became the first FDA-approved mitochondria-targeting drug in September 2025, cleared for Barth syndrome muscle weakness. No human neurological trials have been completed for either peptide.
- 2.SS-31 works by binding cardiolipin on the mitochondrial inner membrane, restoring electron transport chain function and cutting reactive oxygen species. BPC-157 works by shifting the nitric oxide balance from inflammatory iNOS to reparative eNOS, while also upregulating BDNF.
- 3.These two peptides target different nodes of the same neurological failure cascade. SS-31 addresses the upstream energy problem. BPC-157 addresses the downstream vascular and neurotransmitter problem. They complement rather than compete.
- 4.A 2020 study in Brain and Behavior found BPC-157-treated rats recovered full neurological function after ischemic stroke by 72 hours. A 2021 study in Frontiers in Aging Neuroscience found SS-31 improved hippocampal connectivity and memory 30 days after inflammatory brain injury in aged rats.
- 5.The FDA pharmacy advisory committee met July 23-24, 2026 and recommended against adding BPC-157 to the 503A compounding list. SS-31 requires a prescription but has no compounding restrictions. This regulatory gap is now clinically significant.
In September 2025, SS-31 became the first mitochondria-targeting drug ever approved by the FDA. The following month, BPC-157 was listed as under active review for a potential US compounding ban. Two neuroprotective peptides, both with compelling preclinical data, both at a regulatory crossroads at the same time.
Most peptide sites treat SS-31 and BPC-157 as interchangeable options for brain and nervous system recovery. That framing gets the biology wrong. These peptides fix different stages of neurological injury. Using the right one at the right time produces better outcomes than using either one indiscriminately.
Completed human neurological trials for either peptide
As of July 2026, no completed human clinical trial exists for SS-31 or BPC-157 in neurological indications. SS-31 has completed Phase 3 trials in cardiac and mitochondrial muscle disease. BPC-157 has never completed a Phase 1 trial. All neurological evidence for both peptides comes from animal models.
Here is what the preclinical data says, why the mechanisms matter, and how to think about each one for concussion, TBI, stroke recovery, and chronic neurological dysfunction.
Plain English
Think of neurological injury like a city after a major storm. SS-31 is the power company restoring electricity to the grid. Without power, nothing else works: sewage pumps fail, traffic lights go dark, hospitals run on backup. BPC-157 is the road crew repairing streets and water lines after the power comes back on. Both are essential. But if the grid is still down, resurfacing roads is premature. Understanding which job needs doing first is the point of this article.
How does SS-31 actually protect neurons? (The mitochondrial story)
SS-31, now known as Elamipretide, is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane by binding cardiolipin. Cardiolipin is a phospholipid unique to the mitochondrial inner membrane. It holds the electron transport chain complexes in the precise geometric arrangement they need to generate ATP efficiently.
When neurons are injured, the first thing that fails is mitochondrial ATP production. Cardiolipin oxidizes within minutes of injury, disrupting electron transport chain architecture. The result: energy failure, cytochrome c release (which triggers cell death), and a flood of reactive oxygen species that damage surrounding tissue.
SS-31 prevents this cascade by protecting cardiolipin from oxidation. A 2021 study in Frontiers in Aging Neuroscience by Guo and colleagues gave aged rats SS-31 after LPS-induced neuroinflammation. Treated rats showed lower inflammatory cytokines, reduced hippocampal astrocyte activation, improved memory performance on the Morris water maze, and measurably better functional brain connectivity across motor and sensory cortices. Effects persisted 30 days out.
A 2023 study in the Journal of Neuroinflammation found SS-31 blocked cPLA2-driven pyroptosis (a form of inflammatory cell death) in contused spinal cord tissue, preserving tissue architecture at the lesion site. A 2026 paper in Nitric Oxide found SS-31-treated spinal cord injury animals had significantly better functional recovery scores at 28 days, reduced lesion volume, higher MAP2 neuronal marker expression, and more preserved synapses versus controls.
What makes SS-31 suited to the acute phase
The mitochondrial failure SS-31 targets happens within minutes to hours of injury. That timing window is why SS-31 is best understood as an acute-phase intervention: its protective mechanism is most relevant in the first 6-72 hours after injury, when cardiolipin oxidation and cytochrome c release are driving the primary wave of cell death.
In the subacute and chronic phases (weeks to months post-injury), mitochondrial dysfunction persists but is no longer the only failure mode. Vascular dysfunction, neurotransmitter dysregulation, and impaired neuroplasticity all come online. That is where BPC-157 becomes the relevant peptide.
How does BPC-157 repair brain injury? (The NO and BDNF story)
BPC-157 acts primarily on the nitric oxide system and VEGF-driven angiogenesis, not on mitochondria. It does not bind cardiolipin. Its effects on the nervous system run through a completely different set of receptors.
The finding that most articles miss: BPC-157 does not simply increase nitric oxide. It shifts the balance between iNOS (inducible nitric oxide synthase, inflammatory) and eNOS (endothelial nitric oxide synthase, vascular and protective). After TBI or stroke, iNOS is massively upregulated and generates toxic levels of NO that directly inhibit mitochondrial Complex I and IV. BPC-157 suppresses iNOS and activates eNOS simultaneously. The result is less neurotoxic NO and more vasodilatory, pro-repair NO at the same time.
A 2020 study in Brain and Behavior by Vukojević and colleagues applied 20 minutes of bilateral carotid clamping to rats, a standard ischemic stroke model. BPC-157-treated animals showed full functional recovery on lateral push, inclined beam-walking, and Morris water maze within 72 hours of reperfusion. Gene expression analysis confirmed upregulation of eNOS, nNOS, VEGFR2, and Akt1 with simultaneous downregulation of iNOS and NF-kB.
"Pentadecapeptide BPC 157 counteracted all the deficits and reversed them fully in rats after bilateral common carotid occlusion, with a consistent pattern of eNOS upregulation and iNOS downregulation across multiple brain regions."
Vukojevic et al., Brain and Behavior, 2020
A 2022 review in Neural Regeneration Research by Vukojević, Milavić, Sikirić and colleagues synthesized CNS findings from stroke, spinal compression, and dopamine-disruption models. BPC-157 reversed tail paralysis after spinal cord compression, counteracted L-NAME-induced catalepsy (a pure NOS-blockade model), and resolved dopamine and serotonin disruption. The unified finding: BPC-157 normalizes the entire neurotransmitter system by fixing the nitric oxide foundation first.
The iNOS vs eNOS distinction that determines outcomes
Excessive iNOS-derived NO directly inhibits mitochondrial Complex I and IV by binding their heme groups. After TBI, iNOS activity drives NO levels close to double their baseline within 4 hours of injury, per fluid percussion injury models. This creates a feedback loop: mitochondria fail, energy production collapses, more inflammatory signaling drives more iNOS, which damages mitochondria further.
SS-31 breaks this loop upstream by protecting mitochondria directly. BPC-157 breaks it downstream by suppressing iNOS. These are not competing approaches. They are sequential interventions targeting the same cascade from different ends. For a full walkthrough of BPC-157's mechanism and what happens in the hours after a dose, see what happens in the 4 hours after your first BPC-157 injection.
SS-31 vs BPC-157 for neurological recovery: the direct comparison
Upstream mitochondrial protection. Binds cardiolipin. Prevents ATP failure and cytochrome c release. Best for the acute phase, first 6-72 hours. Reduces inflammatory cytokines and astrocyte activation. FDA approved for Barth syndrome since September 2025. No US compounding restrictions. Prescription required.
Downstream vascular and neurotransmitter repair. Shifts iNOS to eNOS. Activates VEGFR2/Akt angiogenesis. Upregulates BDNF. Best for subacute and chronic recovery phases. No FDA approval. Compounding future uncertain after the July 2026 PCAC recommendation. Full functional recovery documented in 72-hour stroke model.
| Factor | SS-31 (Elamipretide) | BPC-157 |
|---|---|---|
| Primary target | Mitochondrial cardiolipin | eNOS/iNOS balance, VEGFR2 |
| Best phase | Acute (0-72 hours post-injury) | Subacute to chronic (day 3 onward) |
| Key mechanism | ATP rescue, ROS reduction, cytochrome c prevention | Vascular repair, NO normalization, BDNF upregulation |
| Neuroinflammation | Reduces cytokines via mitochondrial stabilization | Suppresses NF-kB, shifts iNOS to eNOS |
| Human neuro trials | None completed (Phase 1/2 for LHON, FRDA ongoing) | None completed (no active trials registered) |
| FDA status | Approved (Barth syndrome, September 2025) | No approval, compounding status uncertain |
| Typical neuro dose | 0.1 mg/kg subcutaneous (off-label extrapolation) | 250-500 mcg/day subcutaneous or intranasal |
| Route | Subcutaneous injection or IV (clinical) | Subcutaneous injection, intranasal, or oral |
The table makes the answer look clean. In practice the choice is harder, because you often do not know which mechanism is the primary driver in your case. A clinical TBI with documented mitochondrial dysfunction is an obvious SS-31 candidate. Post-concussion syndrome with persistent brain fog, dysautonomia, and disrupted sleep is more likely driven by chronic NO dysregulation and BDNF deficits: a BPC-157 picture.
Time to full neurological recovery in the BPC-157 stroke model
Rats given BPC-157 after 20-minute bilateral carotid occlusion recovered full performance on all neurological tests within 72 hours of reperfusion, per Vukojević et al., Brain and Behavior, 2020. Controls failed every test at every time point.
When SS-31 outperforms BPC-157 for neurological recovery
SS-31 is the priority peptide in three scenarios. The first is acute TBI within the 72-hour window. The second is any neurological condition where mitochondrial dysfunction is the confirmed or likely primary driver: hereditary optic neuropathy, Friedreich's ataxia, post-ischemia recovery. The third is chronic neurodegeneration where bioenergetic failure is driving progression, including early-stage Alzheimer's and Parkinson's.
The animal data shows SS-31 prevents neuronal death from energy failure rather than repairing neurons after they die. That acute protective window is why timing matters more for SS-31 than for any other neuroprotective peptide discussed here. The earlier in the injury cascade, the more benefit available.
SS-31 also has the cleaner regulatory path right now. As the commercial pharmaceutical Forzinity, it exists as a legitimate drug with an active NDA on file at the FDA. Off-label use for neurological applications requires a prescribing physician but carries no legal ambiguity around procurement. That is a practical advantage over BPC-157 in 2026.
When BPC-157 outperforms SS-31 for neurological recovery
BPC-157 is the better choice when the primary problem is vascular: disrupted cerebral blood flow, damaged microcirculation, or the neurotransmitter dysregulation that follows NO-pathway dysfunction. Post-concussion syndrome fits this picture closely. The persistent headaches, brain fog, dysautonomia, sleep disruption, and mood changes of PCS map to the eNOS/iNOS imbalance that BPC-157 corrects.
BPC-157 also has a BDNF mechanism that SS-31 does not cover. A 2024 review in Pharmaceuticals by Sikirić and colleagues compiled evidence across 30 years of BPC-157 CNS research, documenting BDNF upregulation as a consistent finding across dopaminergic, serotonergic, and glutamate disruption models. For conditions where neuroplasticity is the limiting factor (depression after TBI, learning and memory deficits, recovery from chronic stress), the BDNF mechanism adds a dimension SS-31 simply does not provide.
For a full breakdown of BPC-157 specifically for TBI and spinal injury, see BPC-157 for brain injury and neuroprotection. For the complete SS-31 evidence base, see our SS-31 deep dive.
Can you stack SS-31 and BPC-157 for neurological recovery?
The mechanisms are complementary and non-overlapping. SS-31 targets the inner mitochondrial membrane. BPC-157 targets cell surface receptors, the NO pathway, and VEGF signaling. There is no known antagonism between them. The scientific rationale for stacking is solid: hit the upstream energy problem with SS-31 and the downstream vascular and neurochemical problem with BPC-157.
A sequenced approach makes more biological sense than simultaneous dosing from day one. SS-31 in the acute phase (days 1-7 after injury), then introduce BPC-157 from day 3 onward as the vascular repair and neuroplasticity phases come online. For chronic conditions where the acute phase is long past, either can be introduced independently or together.
No animal study has tested this specific combination for neurological outcomes. The stacking rationale is mechanistic, not empirical. That caveat matters.
What the 2026 regulatory picture means for your protocol
This section matters more right now than it would have a year ago.
SS-31 received FDA accelerated approval in September 2025 under the brand name Forzinity, for muscle strength improvement in Barth syndrome. It is a legitimate pharmaceutical (NDA 215244Orig1s000 on file at FDA). Off-label use for neurological applications requires a physician willing to prescribe outside the approved indication. That is not unusual in peptide medicine, and it is a legally clean path with no gray area around procurement.
BPC-157 is in a different position. On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee met to evaluate BPC-157 for addition to the 503A Bulks List, which would have clarified its legal path through US compounding pharmacies. The committee recommended against adding it. That recommendation is advisory and non-binding. Formal rulemaking and a final rule are still required before any enforcement change. But the direction of travel is not favorable, and access may tighten in the next 12-18 months.
The practical implication: if you are building a neurological recovery protocol today, SS-31 has a more stable regulatory foundation. For an updated breakdown of legal peptide access by US state, see are peptides legal in the US (2026 guide). And for an overview of the BPC-157 landscape including sourcing considerations, see the BPC-157 peptide page.
Which genes predict your response to each peptide?
No published study has linked specific SNPs to differential neurological response for SS-31 or BPC-157 directly. But the biology is clear enough to make educated calls.
For SS-31, the relevant genetics center on mitochondrial function and baseline oxidative stress. APOE4 carriers show higher neuroinflammation and mitochondrial dysfunction after injury compared to APOE3 carriers. SS-31's upstream protection matters more for APOE4 carriers in the acute phase. Mitochondrial DNA haplogroup variants that reduce baseline Complex I efficiency also increase the absolute benefit available from cardiolipin stabilization.
For BPC-157, the relevant genetics are in the nitric oxide and BDNF pathways. NOS3 T-allele carriers (the nitric oxide synthase gene) produce less baseline endothelial NO. BPC-157's eNOS activation adds more relative value for them. BDNF Val66Met Met carriers have impaired secretion-dependent BDNF release but intact transcriptional BDNF pathways. Since BPC-157 works through transcriptional upregulation, it may preserve more cognitive benefit for Met carriers than exercise protocols that rely on secretion.
Your full genetic profile: which peptides match your mitochondrial genetics, your NO pathway variants, and your neuroplasticity genes: is exactly what the PeptidesDNA report covers. It reads your raw 23andMe or AncestryDNA file and ranks 25+ peptides by genetic match. See what your data shows at upload your DNA file or order a saliva kit.
SS-31 and BPC-157 are not interchangeable neuroprotective peptides. SS-31 is the upstream intervention: it protects mitochondria from energy failure in the acute phase, with FDA approval on record and no US compounding restrictions. BPC-157 is the downstream intervention: it repairs vascular function, normalizes the nitric oxide system, and drives BDNF-dependent neuroplasticity in the subacute and chronic recovery phases, with strong preclinical data and increasingly uncertain US access. For most recovery protocols, both are relevant. The mechanism difference tells you which comes first.
Your DNA shapes how you respond to each of these.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
Is SS-31 (Elamipretide) FDA approved for brain injury?
SS-31 (brand name Forzinity) was FDA approved in September 2025, but only for muscle strength improvement in Barth syndrome. It has no approved neurological indication. Use for TBI, concussion, or neuroprotection would be off-label and requires a physician prescription. The FDA approval does confirm the compound's safety and manufacturing standards, which matters for sourcing quality.
Can you take SS-31 and BPC-157 together?
The mechanisms are complementary and there is no known antagonism between them. SS-31 targets the inner mitochondrial membrane; BPC-157 targets eNOS/iNOS balance and VEGF signaling at cell surface receptors. A sequenced approach makes the most biological sense: SS-31 in the acute phase (first few days after injury) then BPC-157 from day 3 onward. No animal study has tested this specific combination for neurological outcomes, so the rationale is mechanistic rather than empirical.
What is the difference between SS-31 and BPC-157 for concussion?
For acute concussion in the first 72 hours, SS-31's mitochondrial protection is more directly relevant because mitochondrial energy failure is the primary driver of secondary neuronal death in this window. For post-concussion syndrome (weeks to months after the initial injury), BPC-157's vascular repair and BDNF mechanisms are more relevant. Persistent brain fog, dysautonomia, and mood changes in PCS map more closely to the NO pathway dysfunction that BPC-157 corrects.
Is BPC-157 still legal to buy in the US in 2026?
The situation is unsettled as of July 2026. BPC-157 has been available through US compounding pharmacies. The FDA's Pharmacy Compounding Advisory Committee met on July 23-24, 2026 and recommended against adding BPC-157 to the 503A Bulks List. That recommendation is advisory and non-binding. Formal rulemaking is still required before any enforcement change. Access may tighten in the next 12-18 months depending on the FDA's final rulemaking.
What dose of SS-31 is used off-label for neurological applications?
There is no established human dose for neurological applications. Animal studies typically use 0.1 mg/kg. The approved Barth syndrome dose (the only human reference point) is weight-based and determined by physicians. Off-label neurological use requires a prescribing physician who will set the dose based on the specific condition and patient profile. Do not self-dose based on animal model extrapolations.
Which peptide works faster for brain recovery?
SS-31 acts faster at the mitochondrial level, stabilizing the electron transport chain within hours of administration. BPC-157 produces measurable vascular and functional recovery on a slightly longer timeline. A 2020 study showed full neurological function in BPC-157-treated stroke rats by 72 hours. The more useful question is not speed: it is which mechanism is the limiting step in your specific case. Both are early-intervention peptides relative to growth factors or regenerative approaches.
Does your APOE4 gene status change which neuroprotective peptide to prioritize?
APOE4 is associated with higher baseline neuroinflammation and greater mitochondrial dysfunction after neurological injury than APOE3. This suggests SS-31's upstream mitochondrial protection may be proportionally more valuable for APOE4 carriers in the acute phase. No study has directly tested APOE4-stratified response to either SS-31 or BPC-157. The PeptidesDNA genetic report covers APOE4 status and its implications across the full peptide panel.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.